The estimated Net Worth of Pericles Calias is at least $154 Thousand dollars as of 10 December 2019. Pericles Calias owns over 2,913 units of Cerecor Inc stock worth over $153,714 and over the last 6 years Pericles sold CERC stock worth over $0.
Pericles has made over 2 trades of the Cerecor Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Pericles bought 2,913 units of CERC stock worth $8,302 on 10 December 2019.
The largest trade Pericles's ever made was buying 4,549 units of Cerecor Inc stock on 10 June 2019 worth over $12,965. On average, Pericles trades about 1,244 units every 31 days since 2018. As of 10 December 2019 Pericles still owns at least 52,462 units of Cerecor Inc stock.
You can see the complete history of Pericles Calias stock trades at the bottom of the page.
Pericles's mailing address filed with the SEC is C/O CERECOR INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
Cerecor Inc executives and other stock owners filed with the SEC include: